GlassScriptPhysician profile
Brandee Bocage
NPI 1124565510
$6,334.01
in general payments reported to CMS, 2019-2025
40 companies · $1,353 in 2025
The $1,353 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,693 · 2022: $1,159 · 2023: $1,093 · 2024: $1,037 · 2025: $1,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,482.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,136.02 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $687.85 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $682.14 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Corcept Therapeutics | $429.18 | 2023-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $347.69 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $264.42 | 2021-2025 | Wegovy, Ozempic |
| Vanda Pharmaceuticals INC. | $256.35 | 2021-2025 | Fanapt, Hetlioz |
| Glaxosmithkline, LLC. | $244.97 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $231.32 | 2022-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $223.86 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $189.13 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.71 | 2021-2024 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $168.56 | 2022-2024 | Austedo Xr |
| Acadia Pharmaceuticals INC | $160.40 | 2021-2022 | |
| Genzyme Corporation | $120.41 | 2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $116.31 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Lilly USA, LLC | $97.22 | 2021-2023 | Trulicity |
| Ucb, INC. | $95.49 | 2022-2024 | Briviact |
| Avanir Pharmaceuticals, INC. | $76.33 | 2021-2022 | |
| Almatica Pharma LLC | $64.42 | 2021-2022 | |
| Lundbeck LLC | $61.16 | 2023-2025 | Rexulti |
| Pfizer INC. | $48.04 | 2021-2024 | |
| Kowa Pharmaceuticals America, INC. | $46.07 | 2021-2025 | Zoryve |
| Scilex Pharmaceuticals INC. | $38.19 | 2021 | |
| Abbott Laboratories | $37.62 | 2021 | |
| Neurelis, INC. | $35.74 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.62 | 2021 | |
| Ardelyx, INC. | $25.99 | 2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $25.03 | 2025 | Zenpep |
| Dexcom, INC. | $23.87 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $23.84 | 2024 | Keveyis |
| Jazz Pharmaceuticals INC. | $23.28 | 2021 | |
| Mylan Specialty L.P. | $22.83 | 2021 | |
| Indivior INC. | $21.47 | 2023 | Sublocade |
| Biogen, INC. | $20.83 | 2021 | |
| Astellas Pharma US INC | $20.25 | 2025 | Veozah |
| Exact Sciences Corporation | $16.16 | 2025 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $15.59 | 2022 | |
| Inspire Medical Systems, INC. | $15.35 | 2023 | Inspire |
| Emd Serono, INC. | $15.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandee Bocage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.